Aurobindo Pharma has notified the stock exchanges of an upcoming Board of Directors meeting scheduled in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting is set to take place on Thursday, May 21, 2026, and will deliberate on key financial disclosures for the recently concluded fiscal year. Subsequently, the company has also announced an Analyst/Investor Earnings Call scheduled for Friday, May 22, 2026, pursuant to Regulation 30(2) of SEBI (LODR) Regulations, 2015. Both intimations were signed by B. Adi Reddy, Company Secretary.

Board Meeting to Consider Q4 and FY26 Financial Results

The primary agenda of the board meeting is to consider and approve the standalone and consolidated audited financial results of the company for the fourth quarter and financial year ended March 31, 2026. The intimation was communicated to both the National Stock Exchange of India Limited and BSE Limited on May 12, 2026.

The key details of the scheduled board meeting are as follows:

Q4FY26 Earnings Call Details

Following the board meeting, Aurobindo Pharma has scheduled an Analyst/Investor Earnings Call on Friday, May 22, 2026 at 8:30 AM IST, to discuss the audited financial results for the fourth quarter and year ended March 31, 2026. The earnings call intimation was filed with the exchanges on May 14, 2026. The earnings presentation will be made available on the company's website post results announcement.

Trading Window Closure Details

In line with the company's earlier communication dated March 23, 2026, the Trading Window had been closed from April 1, 2026, pending the declaration of the audited financial results. The company has confirmed that the Trading Window will remain closed until May 23, 2026, and will be reopened on May 24, 2026, following the customary 48-hour period after the declaration of results.

The Trading Window timeline is summarised below:

The intimations were issued from Aurobindo Pharma's corporate office located at Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Aurobindo Pharma witnessed a notable block trade on the National Stock Exchange (NSE), with approximately 2,00,977 shares changing hands in a single transaction. The trade was executed at a price of ₹1,496.50 per share, aggregating to a total deal value of ₹30.08 crores. Block trades of this scale are typically associated with large institutional investors and reflect significant activity in the counter.

Block Trade Details

The following table summarises the key parameters of the block trade recorded on the NSE:

Key Highlights

• The block trade involved approximately 2,00,977 shares of Aurobindo Pharma.
• The transaction was executed at ₹1,496.50 per share on the NSE.
• The aggregate deal value stood at ₹30.08 crores.

Block trades are privately negotiated transactions executed outside the open market, typically involving large quantities of securities. Such trades are commonly undertaken by institutional investors and may reflect portfolio rebalancing or strategic position changes by major market participants.